Next Article in Journal / Special Issue
Renal Impairment in Chronic Hepatitis B: A Review
Previous Article in Journal
Pancreatic Cystic Lesions: Pathogenesis and Malignant Potential
Previous Article in Special Issue
Survival and Prognostic Factors in Mixed Cryoglobulinemia: Data from 246 Cases
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessCommunication
Diseases 2018, 6(2), 51; https://doi.org/10.3390/diseases6020051

Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida

Division of Infectious Diseases, Department of Medicine, University of Miami. Miller School of Medicine, Miami, FL 33136, USA
Received: 24 May 2018 / Revised: 16 June 2018 / Accepted: 18 June 2018 / Published: 19 June 2018
(This article belongs to the Special Issue Hepatitis and Treatment)
Full-Text   |   PDF [357 KB, uploaded 19 June 2018]   |  

Abstract

Introduction: The new direct acting antivirals (DAA) have demonstrated low rates of adverse effects in controlled studies. However, real world-studies have disclosed emerging toxicities and drug-drug interactions in special populations. Methods: We conducted a retrospective review of HIV/HCV coinfected patients who were treated with DAA at Jackson Memorial Hospital from 2014 to 2017. Our aim was to determine the adverse effects (AE) and factors that are associated with AE in HIV/HCV individuals who are treated with DAA. Results: There were 78 coinfected patients treated with DAA. AE that were secondary to DAA were reported by 21 (26.9%) patients. The most common AE were fatigue (47.6%), gastrointestinal symptoms (38.1%), anemia (14.3%), and headache (14.3%). In comparison with the rest of the study cohort, the patients who developed AE were more often Caucasian (33.3% vs. 10.5%, p = 0.017) and were more frequently treated with PrOD/Ribavirin (9.5% vs. 0%, p = 0.018). In terms of antiretroviral therapy (ART), there was a trend towards a more frequent use of TDF/FTC + NNRTI (33.3% vs. 14%, p = 0.055). Conclusions: These findings demonstrated good tolerability of DAAs in HIV/HCV coinfected patients. More real-world studies are needed to explore the variables that are associated with AE. View Full-Text
Keywords: adverse effects; Hepatitis C; HIV; direct acting antivirals adverse effects; Hepatitis C; HIV; direct acting antivirals
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Gonzales Zamora, J.A. Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida. Diseases 2018, 6, 51.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top